GlassScriptPhysician profile
Shafiqul Alam
NPI 1649258021
$6,001.75
in general payments reported to CMS, 2019-2025
52 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $459 · 2021: $861 · 2022: $813 · 2023: $946 · 2024: $1,088 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $595.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $578.68 | 2019-2025 | Veozah |
| Abbvie INC. | $520.62 | 2021-2025 | Dalvance, Ubrelvy |
| Lilly USA, LLC | $440.90 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $405.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $366.80 | 2019-2025 | |
| Amgen INC. | $257.98 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.61 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $208.17 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $193.53 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $184.20 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Ani Pharmaceuticals, INC. | $160.47 | 2022-2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $158.66 | 2019-2022 | |
| Exact Sciences Corporation | $135.90 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $128.48 | 2024-2025 | Gemtesa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shafiqul Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.